Asset Details
Do you wish to reserve the book?
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
Do you wish to request the book?
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
2013
Overview
Purpose
The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy.
Methods
A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible.
Results
Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence.
Conclusions
Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.
Publisher
Springer-Verlag,Springer,Springer Nature B.V
Subject
/ Clinical practice guidelines
/ Fibroblast Growth Factor 7 - adverse effects
/ Fibroblast Growth Factor 7 - therapeutic use
/ Fibroblast Growth Factors - adverse effects
/ Fibroblast Growth Factors - therapeutic use
/ Granulocyte Colony-Stimulating Factor - adverse effects
/ Granulocyte Colony-Stimulating Factor - therapeutic use
/ Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects
/ Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
/ Humans
/ Intercellular Signaling Peptides and Proteins - adverse effects
/ Intercellular Signaling Peptides and Proteins - therapeutic use
/ Macrophage colony stimulating factor
/ Medicine
/ Mouth
/ Nursing
/ Oncology
/ Patients
/ Practice Guidelines as Topic
